基于成年人安全数据,Hemogenyx将其CAR- T试验扩展到白血病复发的儿童. Hemogenyx expands its CAR-T trial to children with relapsed leukemia, based on adult safety data.

药剂公司获得批准,扩大其对HG- CT-1的I期试验,该试验是针对复发性或耐药性急性髓性白血病的CAR- T疗法,包括儿科患者. Hemogenyx Pharmaceuticals has received approval to expand its Phase I trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients. 该修正案经MD Anderson机构审查委员会批准,允许根据成人审判的安全和早期效果数据招收儿童和青少年入学。 The amendment, cleared by MD Anderson’s Institutional Review Board, allows enrollment of children and adolescents based on safety and early efficacy data from adult trials. 这一举动标志着在推动为较年青的病人提供治疗选择方面迈出的关键一步,这些病人的治疗方法仍然有限。 The move marks a key step in advancing treatment options for younger patients, for whom therapies remain limited. 该公司总部设在伦敦,美国在纽约市开展业务,计划随着成人和儿科团体入学进展提供最新信息。 The company, based in London with U.S. operations in New York City, plans to provide updates as enrollment progresses in both adult and pediatric groups.